Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price was up 18.8% on Tuesday . The company traded as high as C$0.20 and last traded at C$0.19. Approximately 298,425 shares were traded during mid-day trading, a decline of 40% from the average daily volume of 497,673 shares. The stock had previously closed at C$0.16.
Hemostemix Trading Up 21.9 %
The company’s fifty day moving average is C$0.20 and its 200-day moving average is C$0.12. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07. The firm has a market capitalization of C$28.42 million, a P/E ratio of -5.69 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- What is a buyback in stocks? A comprehensive guide for investors
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- What Are Dividend Champions? How to Invest in the Champions
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
